Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema. » Read More
Big pharma lobbyists for Pfizer couldn't save the Allergan merger deal, is the lobbying bubble bursting before our eyes?
New research suggests that CEO narcissism affects a company's use of tax shelters like the corporate inversions now under fire from the Treasury.
Discussing making America more competitive, as well as the presidential candidates, with Former Medtronic CEO Bill George and Wilbur Ross, WL Ross & Co. Chairman and CEO.
Fred Hassan, Warburg Pincus Managing Director and CNBC Contributor, talks about tax inversions in the pharmaceutical industry and his advice to Pfizer after its deal with Allergan fell through.
If 2015 was a dream year for Wall Street's top dealmakers, 2016 is starting to take a nightmarish turn.
The inversion clampdown makes it more difficult for companies to stay competitive, says Sanford Bernstein's Ronny Gal.
Pfizer is worth a lot more than it is trading at, based on the potential for future spin-offs, explains Bill Smead of Smead Capital Management.
The "Fast Money" traders reveal their final trades of the day.
As the U.S. government looks to curb tax inversions these experts discuss the implications of new laws.
Jim Cramer says the bulls should be thanking the Treasury & Justice departments, even if they accidentally sparked a rally.
Merck CEO Kenneth Frazier said a flawed corporate tax system drives inversion deals that have drawn the government's ire.
Jim Cramer says the bulls should be thanking the Treasury & Justice departments, as they accidentally sparked a rally in these stocks.
The "Fast Money" traders share their final trades of the day.
The "Fast Money" traders play "The Dating Game" for Allergan's potential new partner now that that its deal with Pfizer is off the table.
U.S. stocks closed higher Wednesday, led by gains in health care and energy, after the release of the Fed meeting minutes.
Discussing how moves like the Treasury's new tax inversion rules could affect mergers and acquisitions going forward with Martin Okner, SHM Corporate Navigators Managing Partner, and Nicholas Fortuna, Partner at Allyn & Fortuna
The Pfizer, Allergan merger effort has reignited a debate over corporate inversions, says Yevgeniy Feyman. But US jobs are not really at stake.
CNBC contributors Jared Bernstein and James Pethokoukis react to the regulatory change by the Treasury on taxes.
The Allergan-Pfizer deal has been terminated after the Treasury tightened tax rules, with the FMHR traders.
European markets finished higher Wednesday as investors digested new data out of China, while eyeing the latest moves in the oil price.